We are joined by Professor Francisco Pasquel to discuss the findings, rationale and limitations of the Glargine U300 Hospital Trial, which is being presented at this year’s congress.
Filmed at the American Diabetes Association (ADA) annual meeting 2019, San Francisco, USA.
Questions:
1. What are the major challenges of managing hyperglycemia in the hospital setting? (0:05)
2. What is the rationale for the Glargine U300 Hospital Trial? (1:37)
3. What were the findings of the study? (2:26)
4. What are the limitations of Glargine U300? (2:58)
5. In which type 2 diabetes patients should Glargine U300 be considered and in which ones should it be avoided? (3:38)
Francisco Pasquel has received consulting fees and research support from Merck and consulting fees from Boehringer Ingelheim, Lilly, and AstraZeneca.
touchENDO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
